RECCE-327 has preclinical bactericidal activity against N. gonorrhoeae
Dec. 19, 2023
Recce Pharmaceuticals Ltd. has announced preclinical results from an in vivo study evaluating the antibacterial efficacy of its lead synthetic anti-infective candidate, R-327 (RECCE-327), against Neisseria gonorrhoeae in a mouse vaginal infection model.